Get the Stockscreener App
7.95
4.45%
-0.37
After Hours:
8.17
0.22
+2.77%
Aptevo Therapeutics Inc stock is traded at $7.95, with a volume of 65,700.
It is down -4.45% in the last 24 hours and down -67.28% over the past month.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
See More
Previous Close:
$8.32
Open:
$8.42
24h Volume:
65,700
Relative Volume:
0.55
Market Cap:
$7.44M
Revenue:
$12.99M
Net Income/Loss:
$-23.72M
P/E Ratio:
-0.0817
EPS:
-97.2514
Net Cash Flow:
$-23.28M
1W Performance:
-15.34%
1M Performance:
-67.28%
6M Performance:
-85.47%
1Y Performance:
-99.57%
1-Day Range:
$7.91
$8.46
1-Week Range:
$7.91
$10.66
52-Week Range:
$7.91
$1,976.40
Aptevo Therapeutics Inc Stock (APVO) Company Profile
Name
Aptevo Therapeutics Inc
Sector
Industry
Phone
206-838-0500
Address
2401 4TH AVE., SEATTLE, WA
Compare APVO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APVO
Aptevo Therapeutics Inc
|
7.95 | 7.79M | 12.99M | -23.72M | -23.28M | -97.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Aptevo Therapeutics Inc Stock (APVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-18 | Initiated | Ladenburg Thalmann | Buy |
| Oct-05-17 | Resumed | Piper Jaffray | Overweight |
Aptevo Therapeutics Inc Stock (APVO) Latest News
Aptevo Therapeutics Inc. (APVO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Aptevo Therapeutics announces 1-for-18 reverse stock split - MSN
Aptevo Therapeutics (APVO) Stock Price, Quote, News & History - Benzinga
Aptevo Therapeutics enacts 1-for-18 reverse stock split, shares to trade on split-adjusted basis By Investing.com - Investing.com Australia
Aptevo Therapeutics enacts 1-for-18 reverse stock split, shares to trade on split-adjusted basis - Investing.com Australia
Aptevo Therapeutics Implements 1-for-18 Reverse Stock Split - TipRanks
Aptevo Therapeutics To Implement 1-for-18 Reverse Stock Split - Nasdaq
Aptevo Therapeutics Inc. (APVO) Stock: Plummets 36% Ahead of 1-for-18 Reverse Split - parameter.io
Aptevo Therapeutics Stock Slumps To All-Time Low On Reverse Split Approval - Asianet Newsable
Why Aptevo Therapeutics Shares Are Trading Lower By Around 38%? Here Are Other Stocks Moving In Friday's Mid-Day Session - Benzinga
Aptevo Therapeutics (APVO) Announces 1-for-18 Reverse Stock Spli - GuruFocus
Aptevo Therapeutics stock slumps to all-time low on reverse split approval - MSN
What's Going On With Aptevo Therapeutics Stock Today?Aptevo Therapeutics (NASDAQ:APVO) - Benzinga
Aptevo Therapeutics to implement 1-for-18 reverse stock split By Investing.com - Investing.com Nigeria
US Stocks Mixed; Biohaven Shares Fall - Benzinga
Aptevo Therapeutics to implement 1-for-18 reverse stock split - Investing.com
Aptevo Therapeutics stock tumbles after announcing 1-for-18 reverse split - Investing.com
Aptevo Therapeutics to Conduct 1-for-18 Reverse Stock Split; Shares Fall Pre-Bell - marketscreener.com
Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split - standard-journal.com
Aptevo Therapeutics Inc announces 1-for-18 reverse stock split - marketscreener.com
Biotech firm turns every 18 shares into 1 in year-end stock move - Stock Titan
Total debt per share of Aptevo Therapeutics, Inc. – MUN:AP81 - TradingView — Track All Markets
How analysts rate Aptevo Therapeutics Inc. stock todayMarket Trend Summary & AI Powered Market Entry Ideas - Улправда
Aptevo Therapeutics Earnings Notes - Trefis
Fed Watch: Is Aptevo Therapeutics Inc. stock a buy for dividend growthBull Run & Weekly Watchlist for Hot Stocks - DonanımHaber
Is Aptevo Therapeutics Inc. stock trading at a premium valuation2025 Market Sentiment & Technical Pattern Based Signals - Улправда
Will Aptevo Therapeutics Inc. stock attract ESG investorsJuly 2025 Setups & Community Verified Watchlist Alerts - Улправда
Aug Outlook: Can Aptevo Therapeutics Inc. (AP81) stock withstand sector downturns2025 Top Gainers & Capital Efficient Trading Techniques - Улправда
Will Aptevo Therapeutics Inc. stock outperform Dow Jones indexBond Market & Weekly Breakout Opportunity Watchlist - Улправда
Aptevo Therapeutics presents preliminary results from Phase 1b/2 RAINIER study - MSN
Aptevo Therapeutics Inc AP81 Stock Analysis and ForecastHealthcare Stock Analysis & High Return Trading Strategies - earlytimes.in
Volume Report: Is Aptevo Therapeutics Inc stock supported by strong fundamentalsShare Buyback & Accurate Intraday Trading Signals - moha.gov.vn
Omniab Plans to Launch Its New Omniultra? Transgenic Chicken Platform in December 2025 At the Antibody Engineering & Therapeutics Conference - marketscreener.com
Prepare Yourself for Liftoff: Aptevo Therapeutics Inc (APVO) - setenews.com
Top Pre‑Market Gainers Today, December 10, 2025: ASPC, ENVB, BDRX and APVO Lead Fed‑Day Frenzy - ts2.tech
Aptevo Therapeutics Announces Promising RAINIER Trial Results - TipRanks
Aptevo’s AML therapy shows strong safety profile in phase 1b/2 trial - Investing.com
Aptevo Therapeutics Highlights Compelling Safety and Strong Remission Rates for Mipletamig in Frontline AML at ASH 2025 - ACCESS Newswire
Aptevo Therapeutics (NASDAQ: APVO) shows 100% CRS-free safety, 87% CR/CRi in AML - Stock Titan
Aptevo Therapeutics Inc Stock (APVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):